Rebecca Moore

Rebecca Moore works in SpyBiotech’s adenoviral team developing vaccines targeting infectious diseases and cancer.

Rebecca joined SpyBiotech at the end of 2021 from the Sir William Dunn School of Pathology, Oxford University, where she spent several years working on HIV-1 biology and vaccine development. Prior to this, Rebecca worked at the National Cancer Institute in Frederick, MD, USA, on the HIV-1 restriction factor APOBEC3G.

Rebecca obtained a PhD in Gene Therapy from Imperial College, London, where she worked on adenoviral vectors.